GSK strikes up to $750 million deal for cancer-targeting drug
Sept 15 (Reuters) - GSK GSK.L said on Tuesday it had agreed to a deal worth up to $750 million to buy a trispecific T cell-engager, a drug designed to help T-cells target cancer, from private biotechnology firm Chimagen Biosciences.